| Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb M Khan, SJ Yoo, M Clijsters, W Backaert, A Vanstapel, K Speleman, ... Cell 184 (24), 5932-5949. e15, 2021 | 289 | 2021 |
| Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of … J Prattes, J Wauters, DR Giacobbe, J Salmanton-García, J Maertens, ... Clinical Microbiology and Infection 28 (4), 580-587, 2022 | 165 | 2022 |
| Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 … AS Neto, CSV Barbas, FD Simonis, A Artigas-Raventós, J Canet, ... The Lancet Respiratory Medicine 4 (11), 882-893, 2016 | 151 | 2016 |
| Multinational observational cohort study of COVID-19–associated pulmonary aspergillosis NAF Janssen, R Nyga, L Vanderbeke, C Jacobs, M Ergün, JB Buil, ... Emerging infectious diseases 27 (11), 2892, 2021 | 99 | 2021 |
| Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial L Vanderbeke, NAF Janssen, DCJJ Bergmans, M Bourgeois, JB Buil, ... Intensive care medicine 47 (6), 674-686, 2021 | 63 | 2021 |
| Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo … B François, HS Jafri, J Chastre, M Sánchez-García, P Eggimann, ... The lancet infectious diseases 21 (9), 1313-1323, 2021 | 59 | 2021 |
| Evidence of a preprogrammed deactivation of the hamstring muscles for triggering rapid changes of posture in humans G Chéron, A Bengoetxea, T Pozzo, M Bourgeois, JP Draye Electroencephalography and Clinical Neurophysiology/Electromyography and …, 1997 | 58 | 1997 |
| Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion JJ De Waele, I Danneels, P Depuydt, J Decruyenaere, M Bourgeois, ... International journal of antimicrobial agents 41 (5), 434-438, 2013 | 46 | 2013 |
| TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND … AMF Froon, JWM Greve, WA Buurman, CJ van der Linden, ... Shock 5 (5), 313-319, 1996 | 44 | 1996 |
| In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study R Lorusso, ME De Piero, S Mariani, M Di Mauro, T Folliguet, FS Taccone, ... The Lancet Respiratory Medicine 11 (2), 151-162, 2023 | 36 | 2023 |
| How is equity approached in universal health coverage? An analysis of global and country policy documents in Benin and Senegal E Paul, C Deville, O Bodson, NE Sambiéni, I Thiam, M Bourgeois, ... International journal for equity in health 18, 1-21, 2019 | 32 | 2019 |
| Impact of a VAP bundle in Belgian intensive care units L Jadot, L Huyghens, A De Jaeger, M Bourgeois, D Biarent, A Higuet, ... Annals of intensive care 8, 1-7, 2018 | 32 | 2018 |
| Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically … J Chastre, B François, M Bourgeois, A Komnos, R Ferrer, G Rahav, ... Critical Care 26 (1), 355, 2022 | 26 | 2022 |
| Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015–20: a surveillance study N Fischer, N Dauby, N Bossuyt, M Reynders, M Gérard, P Lacor, ... The Lancet Microbe 2 (3), e105-e114, 2021 | 21 | 2021 |
| Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome … L Pisani, AG Algera, AS Neto, L Azevedo, T Pham, F Paulus, ... The Lancet global health 10 (2), e227-e235, 2022 | 20 | 2022 |
| 635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically … J Chastre, B François, M Bourgeois, A Komnos, R Ferrer, G Rahav, ... Open Forum Infectious Diseases 7 (Supplement_1), S377-S378, 2020 | 20 | 2020 |
| Prognostic impact of bronchoalveolar lavage fluid galactomannan and aspergillus culture results on survival in COVID-19 intensive care unit patients: a post hoc analysis from … DR Giacobbe, J Prattes, J Wauters, S Dettori, A Signori, ... Journal of clinical microbiology 60 (4), e02298-21, 2022 | 19 | 2022 |
| Efficiency of autologous stem cell collection: comparison of three different cell separators V Deneys, A Fabry, M Van Hooydonk, A Sonet, M André, M Bourgeois, ... Transfusion and Apheresis Science 56 (1), 35-38, 2017 | 15 | 2017 |
| Budgeting challenges on the path towards universal health coverage: the case of Benin E Paul, NE Sambiéni, JP Wangbe, F Fecher, M Bourgeois Health Economics Review 10, 1-8, 2020 | 12 | 2020 |
| Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19 L Subissi, N Bossuyt, M Reynders, M Gérard, N Dauby, M Bourgeois, ... Eurosurveillance 25 (39), 1900627, 2020 | 12 | 2020 |
